Trials / Unknown
UnknownNCT02797041
Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.
REal Life, Retrospective Study of BOrtezomib Use as secoND Treatment for Myeloma Patients Previously Exposed to Bortezomib-based Therapies as First Line
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- IRCCS Centro di Riferimento Oncologico della Basilicata · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational, non-interventional, retrospective, multicenter, national study focuses on collecting information about the effectiveness and safety of bortezomib re-use at first relapse in MM patients already treated in their first line with a bortezomib-based regimen, re-challenged with the same drug according to current clinical practice and/or Italian SIE/SIES/GITMO, IMWG and/or NCCN Guidelines/Treatment Recommendations. Data will be collected retrospectively from approximately 25 haematologic/oncologic sites in Italy. Approximately, data of up to 100 patients will be collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bortezomib | Re-challenge with bortezomib as second line therapy in myeloma patients relapsed after a previous bortezomib-based treatment |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2016-03-01
- Completion
- 2016-06-01
- First posted
- 2016-06-13
- Last updated
- 2016-06-14
Source: ClinicalTrials.gov record NCT02797041. Inclusion in this directory is not an endorsement.